Integra LifeSciences (IART) Q2 FY26 earnings call

Integra LifeSciences delivered solid Q2 FY26 results, driven by improved operational execution and supply reliability, leading to an EPS beat. The company reaffirmed its full-year organic revenue and adjusted EPS guidance, leveraging cost savings and tariff favorability to offset anticipated higher interest expenses. Strategic initiatives, including the successful Primatrix relaunch and the upcoming Surgimend relaunch with its PMA strategy, are strengthening the foundation for sustainable long-term growth, despite some segment-specific headwinds.